Simplex Trading
IMUC

Simplex Trading’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Simplex Trading’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Hold
0
– -$2K – 6961
2015
Q2 		– Hold
0
– – – 4525

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Simplex Trading's IMUC Position: Q3 2015 in Review

Simplex Trading sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2015, closing a stake of 25 shares.

Simplex Trading first reported a position in IMUC in Q2 2015 and held it in 1 quarter. The position peaked at $0 in Q2 2015. 28 funds tracked by Wall St. Rank hold IMUC as of Q3 2015.

  • Simplex Trading reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2015 after selling out during the quarter.
  • Simplex Trading sold 25 ImmunoCellular Therapeutics, Ltd. shares in Q3 2015.
  • Simplex Trading first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2015 and held it in 1 quarter.
  • Simplex Trading's ImmunoCellular Therapeutics, Ltd. position peaked at $0 in Q2 2015.
  • 28 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2015.

Based on Simplex Trading's 13F filing for Q3 2015, filed 8 Oct 2015.